Objetivo: El cáncer infantil es una enfermedad que modifica el estilo y calidad de vida de los niños y sus familias debido al impacto físico, emocional y económico que provoca. Los Cuidados Paliativos Pediátricos tienen entre sus funciones otorgar atención psicológica a los niños y sus familiares desde la etapa prediagnóstica con la finalidad de mejorar el estado anímico del paciente y promover pensamientos y conductas que le permitan adaptarse a su nueva condición y mejoren la adherencia al tratamiento. Se expone el caso de una paciente pediátrica con diagnóstico de Sarcoma Sinovial que presenta sintomatología depresiva y evitación ansiosa a raíz de su padecimiento. Método: La evaluación se realizó mediante entrevista conductual y observación directa de la sintomatología ansiosa y depresiva intrahospitalaria y la Escala Visual Análoga (EVA) para el dolor. El tratamiento se llevó a cabo en siete sesiones en las que se emplearon técnicas de la Terapia Cognitivo-Conductual. Resultados: Entre los resultados se obtuvieron verbalizaciones adaptativas sobre su padecimiento, posibles tratamientos médicos, autoconcepto, una mejora en la expresión emocional y control del dolor. Conclusiones: El presente caso es una muestra de la importancia que tiene la labor del psicólogo en los Cuidados Paliativos Pediátricos, así comoel impacto del trabajo con los niños que padecen enfermedades oncológicas y sus familiares. La Terapia Cognitivo-Conductual ha demostrado ser altamente eficaz en este tipo de pacientes, aún en intervenciones breves.
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, yet its pathogenic mechanisms remain incompletely understood, highlighting the need for reliable experimental models. We previously developed a murine model based on inhalation of a manganese mixture (MnCl2 and Mn(OAc)3), which reproduces dopaminergic neuron loss in the substantia nigra pars compacta (SNc) and motor impairment. However, its capacity to mimic mitochondrial dysfunction, a key mechanism in PD, had not been explored. This study evaluated mitochondrial ultrastructure, fission and fusion proteins, and the activity of electron transport chain complexes I and IV, alongside fine motor performance. Forty male CD1 mice were divided into control (deionized water) and manganese-exposed groups (0.04 M MnCl2 + 0.02 M Mn(OAc)3), inhaled for 1 h twice weekly over five months. Manganese inhalation induced significant fine motor deficits, increased mitochondrial number with reduced area and circularity, and disorganized cristae. Drp1 and Fis1 levels were elevated, accompanied by decreased activity of complexes I and IV, predominantly in the SNc. These findings demonstrate that this progressive, bilateral model reproduces mitochondrial and motor alterations resembling those observed in PD, supporting its utility for testing mitochondria-targeted therapeutic strategies.
Parkinson?s disease (PD) higher incidence has been observed in postmenopausal women compared to premenopausal women, suggesting estrogen neuroprotective effect. L-DOPA (LD) chronic treatment causes dyskinesia; evidences indicate that LD increases the preexisting oxidative stress condition. This study determines melatonin ability, alone or in combination with LD (LD/Mel) to protect dopaminergic loss induced by 6-OHDA in a rat PD model in ovariectomized (OVX) and intact (with ovaries (W/OV)) rats on motor behavior and cytological alterations, comparing with LD-only treated rats. LD/Mel-treated rats showed dyskinesia decrease (score 5–7.5) and had the best performance in the staircase test (five pellets) throughout all studies. The beam walking time was 20–35 s, showing good coordination (as control group (20–38 s)), dopaminergic cells increase of 22.8% (W/OV rats) and 27.2% (OVX rats) in the contralateral side as well as 100% conservation in the contralateral dendritic spines. Our results suggest that LD/Mel co-administration and estrogen presence result in an efficient treatment to reduce dyskinesia through the conservation of some dopaminergic cells, which imply a well-preserved neuropil of a less denervated striatum. We assume that these results are because of a synergistic effect between LD, melatonin and estrogens.
Chronic exposure to vanadium pentoxide (V2O5) has been linked to neuronal damage equivalent to that found in Alzheimer’s disease (AD). Prior research has indicated that chronic inhalation of V2O5 results in cellular and behavioral changes akin to those observed in AD. A total of 40 male Wistar rats were categorized into two control groups and two experimental groups for the study. The experimental inhaled V2O5 for 6 months; after 6 months, two groups (control and exposed) were left in a 6-month recovery phase. All groups were evaluated monthly for 6 or 12 months in a spatial memory test. To measure histological alterations, hippocampus CA1, entorhinal and frontal cortices, amygdala, and subiculum underwent Congo red or argentic Bielschowsky impregnation and were analyzed. Memory results show impairment since the third month. The group left in recovery did not show improvement. Chronic V2O5 inhalation is an AD model that causes irreversible alterations in spatial memory, accumulation of Aβ plaques, accumulation of NFTs, and loss of dendritic spines with no recovery. These alterations are not reversible after 6 months, indicating that the damage increases once the neurodegenerative process is established and the homeostasis is broken. This model characterizes sporadic AD, representing more than 95% of cases.
Parkinson’s disease (PD) experimental models are crucial in the assessment of possible therapies. Nevertheless, even though PD was one of the first neurodegenerative conditions to be modeled, there are limitations such as spontaneous recovery; lack of bilateral damage, which is a PD characteristic; animal intensive care after neurotoxin administration; and ultrastructural and biochemical nonspecific alterations but mostly the neurodegenerative time course observed in humans. In this chapter, we investigated the effects of divalent and trivalent manganese inhalation on rats and mice to obtain a novel PD animal model inducing bilateral and progressive dopaminergic cell death. We found that after 5 or 6 months of inhalation, there was more than 70% decrease in the number of TH-immunopositive neurons, and these alterations are correlated with an evident motor performance deficits manifested as akinesia, postural instability, and action tremor. More interesting is the fact that these alterations were reverted with l-DOPA treatment, implying that the motor alterations are associated with nigrostriatal dopaminergic innervation, postulating new light for the understanding of manganese neurotoxicity as an appropriate PD experimental model. Our results are contributing to the development of a suitable PD animal model, reproducible, sensitive, time-efficient, and readily applicable behavioral tests.